TROP2
4 articles
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
AI-Designed Mini-Proteins Replace Antibodies as TROP2-Targeting Drug Carriers for Solid Tumors
- Deep-learning design produced a small protein binder against the tumor antigen TROP2, avoiding animal immunization and antibody screening.
- The binder showed good specificity and thermal stability, and partial diffusion sharpened its affinity by roughly sixty-fold.
- Attaching the microtubule-disrupting payload VcMMAE yielded mini-protein drug conjugates that selectively kill TROP2-positive cancer cells.
- Activity was assessed in cell lines, organoids and mouse xenografts.
A de novo binder skips immunization, but an ADC carrier lives or dies on pharmacokinetics: without an Fc or albumin-binding handle, a mini-protein clears through the kidney fast, and a vcMMAE payload will raise renal and hydrophobicity-driven uptake concerns. I'd want half-life, kidney accumulation and TROP2-negative tissue data, plus a head-to-head against sacituzumab-type ADCs, before calling this an antibody replacement.
Industry NewsMerck / Kelun-BiotechEndpoints News
Merck's R&D Chief Says Breadth Gives sac-TMT the Edge in the TROP2 ADC Race
- In an Endpoints interview, Merck R&D head Dean Li argued the company outflanked rivals on next-generation oncology by pushing sac-TMT, its Kelun-licensed TROP2 ADC, into a wide set of indications.
- He pointed to the gynecologic and gastric cancer programs as where the drug has an advantage over competing TROP2 ADCs.
- Context: sac-TMT recently posted a survival benefit in a Phase 3 endometrial cancer trial, which has FDA priority review.
Li is selling breadth as the moat: with TROP2 ADCs converging on lung and breast, Merck is trying to own tumor types where rivals are absent and where Keytruda combinations are natural. It is a sensible hedge against the Keytruda patent cliff, but the claim is an executive's own read, and it only holds if the gynecologic and gastric trials keep delivering.
Industry NewsMerck / Kelun-BiotechBioSpace
Sac-TMT Beats Chemo on Survival in Endometrial Cancer, a First for a TROP2 ADC
- In the Phase 3 TroFuse-005 trial (about 776 patients), the TROP2 ADC sac-TMT from Merck and Kelun-Biotech outperformed chemotherapy in previously treated advanced or recurrent endometrial cancer.
- Median overall survival reached 19.0 versus 12.1 months, and progression-free survival 7.2 versus 3.9 months.
- Severe treatment-related adverse events were more common with the ADC (54.4% vs 41.4%). The FDA has granted priority review.
A 6.9-month overall survival gain over chemotherapy is a strong result in a TROP2 field where Gilead and Daiichi Sankyo/AstraZeneca already compete, and it gives sac-TMT randomized survival data to lean on. The 13-point gap in severe adverse events will shape its positioning. For Merck, it shows a China-originated ADC moving toward the center of its oncology pipeline.
Industry NewsSummit Therapeutics / AstraZeneca / Daiichi SankyoEndpoints News
Summit, AstraZeneca and Daiichi Sankyo to test ivonescimab plus Datroway, starting with Phase III in 1L TNBC
- Summit, AstraZeneca and Daiichi Sankyo announced a clinical collaboration combining ivonescimab (PD-1xVEGF bispecific) with Datroway (datopotamab deruxtecan, a TROP2-directed ADC).
- It starts with a Phase III study in first-line triple-negative breast cancer, with plans to expand to other settings including lung cancer.
- The companies will share trial costs, and each retains development and commercial rights to its own drug.
Three companies, two assets, and no one gives up rights: this is a cost-sharing structure, not a licensing deal. For Summit, pairing ivonescimab with a validated TROP2 ADC borrows AstraZeneca and Daiichi's TNBC credibility and trial muscle. For the big partners, it is a cheap hedge on the PD-1xVEGF class. I would want to see the control arm and endpoints before judging how much it de-risks.